Disappointment For Novartis As England’s NICE Says No To Migraine Drug Again
Doubts linger over Aimovig's cost effectiveness
Executive Summary
New cost-effectiveness analyses and an improved deal for Aimovig have failed to change the health technology assessment body's mind about routine funding for the migraine prevention drug.